Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Oxycodone Drugs Market Set To Climb From $6.37 Billion In 2026 To $8.06 Billion By 2030
The oxycodone drugs market has experienced robust expansion in recent years. It is projected to grow from $5.98 billion in 2025 to $6.38 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. The surge during the preceding period can be attributed to the high prevalence of moderate to severe pain conditions, the widespread application of opioids in post-operative care, significant hospital demand for injectable analgesics, the established clinical effectiveness of oxycodone, and the limited availability of alternative pain therapies.
The oxycodone drugs market is projected to demonstrate robust growth over the next few years. It is forecast to grow to $8.07 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.1%. This anticipated expansion during the forecast period can be attributed to more rigorous opioid prescribing regulations, the development of controlled-release pain management solutions, an increasing prevalence of cancer and chronic pain cases, the proliferation of pain management clinics, and the creation of safer opioid formulations. Significant trends for the forecast period include a shift towards abuse-deterrent oxycodone formulations, an increasing utilization of extended-release pain management therapies, a growing preference for opioid administration within hospital environments, heightened emphasis on prescription monitoring and compliance, and the expansion of generic oxycodone products across regulated markets.
Get A Free Sample Report With In-Depth Market Insights:
Oxycodone Drugs Market Growth Factors Behind Sustained Expansion
The increasing prevalence of orthopedic conditions is anticipated to drive the expansion of the oxycodone drug market in the future. Orthopedic disorders encompass ailments impacting bones, joints, ligaments, tendons, and muscles, frequently leading to persistent pain, restricted movement, and enduring functional impairments. This escalation in orthopedic issues is fueled by elements like an aging population, inactive lifestyles, obesity, injuries sustained during sports, and work-related physical stress. Oxycodone drugs offer effective pain management by alleviating both acute and chronic orthopedic pain, such as that from fractures, joint damage, and post-operative recovery, by targeting pain receptors within the central nervous system. As an illustration, figures from February 2024, sourced from Arthritis Australia, an Australia-based non-profit organization, predict that in 2025, around 212,136 males and 362,137 females will be affected by rheumatoid arthritis (RA). These numbers are expected to climb by 2040, reaching approximately 280,040 males and 479,828 females. Consequently, the increasing prevalence of orthopedic conditions is a key factor propelling the expansion of the oxycodone drug market.
Oxycodone Drugs Market Segment Landscape And Growth Outlook
The oxycodone drugs market covered in this report is segmented –
1) By Drug Type: Short Acting Oxycodone, Long Acting Oxycodone
2) By Dosage Form: Tablets, Capsules, Injections
3) By Indication: Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Post Operative Pain, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Short Acting Oxycodone: Immediate-Release Oxycodone Tablets, Oxycodone Oral Solution
2) By Long Acting Oxycodone: Extended-Release Oxycodone Tablets, Oxycodone Controlled-Release Formulations
Oxycodone Drugs Market Industry Trends Fueling Future Revenue Growth
Major companies operating in the oxycodone drug market are prioritizing the development of advanced abuse-deterrent immediate-release (IR) formulations to diminish the risk of misuse via injection and intranasal administration. Abuse-deterrent IR opioids incorporate physical and chemical barriers that render tablets difficult to crush, dissolve, or manipulate for non-oral routes, thereby enhancing patient safety and minimizing diversion. For instance, in October 2024, Protega Pharmaceuticals LLC, a US-based pharmaceutical company, received FDA approval for ROXYBOND™ (oxycodone hydrochloride) 10 mg immediate-release tablets, which integrate patented SentryBond abuse-deterrent technology. This technology is engineered to resist physical manipulation and chemical extraction, making the tablets difficult to cut, crush, or dissolve for misuse through intranasal or intravenous routes. Consequently, it lowers the potential for abuse while still delivering effective immediate-release pain relief for patients whose severe pain requires opioid therapy when other treatment options are insufficient.
Oxycodone Drugs Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the oxycodone drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Purdue Pharma L.P, Endo International plc, Amneal Pharmaceuticals LLC, Mundipharma Pty Limited, Alkermes plc, Mallinckrodt Pharmaceuticals, Alvogen Group Inc., Collegium Pharmaceutical Inc., Lannett Company Inc., Acorda Therapeutics Inc., Camurus AB, Rhodes Pharmaceuticals L.P., KVK Tech Inc., Teikoku Pharma USA Inc., Manus Aktteva Biopharma LLP, Zyla Life Sciences
View The Full Oxycodone Drugs Market Report:
Oxycodone Drugs Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the oxycodone drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oxycodone drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
